Table 1.

Outcome parameters from studies on adalimumab in ulcerative colitis

Study (references)	Study type	Number of patients	Induction of clinical response/remission (%)	Maintenance of clinical response/remission (%)	Steroid sparing (%)	Mucosal healing (%)	Colectomy (%)
ULTRA 120	RCT	390	Week 8: 54.6%/18.5%	–	–	Week 8: 46.9%	–
ULTRA 221	RCT	494	Week 8: 50.4%/16.5%	Week 52: 34.6%/17.3%	37.8%	Week 8: 41.1% Week 52: 25%	–
Oussalah et al27	OL	13	–	42 weeks mean FU: 38.5% clinical benefit	–	–	46.2%
Afif et al28	OL	20	Week 8: 25%/5%	Week 24: 50%/25%	58%	–	–
Hudis et al29	RS	9	–	–	56%	–	–
Gies et al30	OL	25	Week 14: 80%/–	54.5 weeks median FU: 70%/–	100%	–	8%
Taxonera et al31	RS	30	Week 12: 60%/26.7%	48 weeks median FU: 50%/–	68%	–	20%
Ferrante et al33	RS	50	Week 4: 68%/–	23 months median FU: 52%/–	–	–	20%
McDermott et al32	RS	23	–	23 months median FU: 35% clinical benefit	–
García-Bosch et al34	RS	48	Week 12: 70.8%/50%	Week 54: 35%/30%	–	–	22.9%
Armuzzi et al35	RS	88	Week 12: –/28.4%	week 54: –/43.2%	56.7%	26.3%	25%

Abbreviations: RCT, randomized controlled trial; OL, open-label study; RS, retrospective study; FU, follow-up.